ADULT LEUKEMIA RESEARCH CENTER

第一次或第二次缓解的ALL患者将包括 随机III期试验中接受治疗的主要患者组 在这个子项目中。 基于来自 纪念斯隆凯特琳移植队的比较将是 在14.4戈伊超分割TBI治疗方案 然后是CY和15.75戈伊的分次TBI方案 在CY之前或之后。 后一种方案的选择 将由正在进行的随机试验的结果决定 比较TBI前后CY的给药情况。 未来 III期试验将采用新的治疗方案设计 一. A.次级项目和I.B. 我们将确定风险因素 与骨髓移植的成功或失败相关， 明确骨髓移植在ALL患者中的作用， 尤其是那些第一次缓解的人。

Patients with ALL in first or second remission will comprise the major patient group treated in randomized phase III trials proposed in this subproject. Based on promising results from the Memorial Sloan Kettering Transplant Team a comparison will be made between a schedule of 14.4 Gy of hyperfractionated TBI followed by CY and a fractionated TBI schedule of 15.75 Gy either preceded or followed by CY. Choice of the latter regimen will be determined by the results of an ongoing randomized trial comparing the administration of CY before or after TBI. Future Phase III trials will be designed using new treatment regimens developed in subprojects I.A. and I.B. We will identify risk factors associated with success or failure of marrow transplantation to define the role of marrow grafting in patients with ALL, especially those in first remission.